Page last updated: 2024-08-23

buserelin and Disease Exacerbation

buserelin has been researched along with Disease Exacerbation in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (66.67)	18.2507
2000's	1 (33.33)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Kojima, M; Ohe, H; Watanabe, H	1
de Pauw, M; de Voogt, HJ; Klijn, JG; Schröder, FH; Studer, U; Sylvester, R	1
Illiger, HJ; Willeke, K	1

Trials

2 trial(s) available for buserelin and Disease Exacerbation

Article	Year
Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis o European urology, 1998, Volume: 33, Issue:2 Topics: Acid Phosphatase; Administration, Intranasal; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Carcinoma; Cause of Death; Cyproterone Acetate; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Injections, Subcutaneous; Male; Middle Aged; Orchiectomy; Pain Measurement; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms; Survival Rate; Treatment Outcome	1998
[Combination therapy with buserelin and tamoxifen in metastatic breast cancer in premenopause: a randomized study]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2001, Volume: 177, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Buserelin; Disease Progression; Disease-Free Survival; Female; Humans; Premenopause; Tamoxifen; Time Factors	2001

Article

Year

Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis o

European urology, 1998, Volume: 33, Issue:2

Topics: Acid Phosphatase; Administration, Intranasal; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Carcinoma; Cause of Death; Cyproterone Acetate; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Injections, Subcutaneous; Male; Middle Aged; Orchiectomy; Pain Measurement; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms; Survival Rate; Treatment Outcome

1998

[Combination therapy with buserelin and tamoxifen in metastatic breast cancer in premenopause: a randomized study].

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2001, Volume: 177, Issue:5

Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Buserelin; Disease Progression; Disease-Free Survival; Female; Humans; Premenopause; Tamoxifen; Time Factors

2001

Other Studies

1 other study(ies) available for buserelin and Disease Exacerbation

Article	Year
Kinetic analysis of prostatic volume in patients with stage D prostatic cancer treated with LHRH analogues in relation to prognosis. British journal of urology, 1995, Volume: 75, Issue:4 Topics: Aged; Aged, 80 and over; Buserelin; Disease Progression; Follicle Stimulating Hormone; Humans; Kinetics; Leuprolide; Luteinizing Hormone; Male; Predictive Value of Tests; Prognosis; Prostate; Prostatic Neoplasms; Survival Analysis	1995

Article

Year

Kinetic analysis of prostatic volume in patients with stage D prostatic cancer treated with LHRH analogues in relation to prognosis.

British journal of urology, 1995, Volume: 75, Issue:4

Topics: Aged; Aged, 80 and over; Buserelin; Disease Progression; Follicle Stimulating Hormone; Humans; Kinetics; Leuprolide; Luteinizing Hormone; Male; Predictive Value of Tests; Prognosis; Prostate; Prostatic Neoplasms; Survival Analysis

1995